Superbugs and Superdrugs-SMi's 12th annual conference--Overcoming resistance. 17-18 March 2010, London, UK.
The 12th Annual Superbugs and Superdrugs conference, held in London, included topics covering new therapeutic developments in the field of antimicrobial research. This conference report highlights selected presentations on antimicrobial peptides, addressing bacterial resistance, and new treatments for bacterial infections. Investigational drugs discussed include DPK-060 (DermaGen AB), DAV-132 (Da Volterra), PF-4287881, PNU-100480 and PF-02538084 (all Pfizer Inc), BAL-30072 (Basilea Pharmaceutica International Ltd) and lanbiotics from Novacta.
Oni
Adekemi
A
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. adekemi.oni@thomsoreuters.com
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015195:Drug Design; D024881:Drug Resistance, Bacterial; D015507:Drugs, Investigational / Q000494:pharmacology*; D006801:Humans; D010455:Peptides / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D015507:Drugs, Investigational; D010455:Peptides